Fractyl's Revita Hits Pivotal Endpoint: 80% Weight Loss Retained vs 67% Sham (p=0.0023)

summarizeSummary

Fractyl's Revita met the six-month co-primary endpoint in its 308-patient REMAIN-1 pivotal study, retaining 80% of GLP-1 weight loss versus 67% for sham (p=0.0023) with no related serious adverse events. The company now plans a De Novo FDA submission in late Q4 2026.

check_boxKey Events · Product Development and Regulatory · GUTS

• Pivotal Endpoint Met With Significance

  In the 308-patient REMAIN-1 Pivotal Cohort, Revita patients retained ~80% of GLP-1-induced weight loss at six months versus 67% for sham (LS-mean regain 5.1% vs 8.2% of body weight; p=0.0023).

• Dose Response Reinforces Mechanism

  Post hoc analysis by ablation length showed 43% less regain at 12-18 cm (4.7% vs 8.2%, p=0.001) and 53% less at >=20 cm (3.8% vs 8.2%, p=0.003), with the treatment effect nearly doubling from Month 3 to Month 6.

• Clean Interim Safety Profile

  No device- or procedure-related serious adverse events, no deaths, and no unanticipated device effects as of the September 24, 2026 data cutoff; 94% of related events occurred within seven days and were predominantly mild.

• De Novo Submission Targeted Late Q4 2026

  Fractyl plans to submit a De Novo marketing application to the FDA in late Q4 2026, with 12-month pivotal data and the second co-primary endpoint (>=5% weight loss maintenance vs a 50% performance goal) expected Q1 2027.

auto_awesomeAnalysis · GUTS · Industrial Applications And Services

This is the binary clinical readout the entire Fractyl thesis rested on, and it hit. In a 308-patient randomized, double-blind, sham-controlled pivotal study, a single Revita procedure kept patients at roughly 80% of their GLP-1-induced weight loss six months after stopping the drug, versus 67% for sham, with high statistical significance (p=0.0023). The effect grew over time and scaled with ablation length (53% less regain at >=20 cm), and there were zero device- or procedure-related serious adverse events. That clears the path to a De Novo FDA submission in late Q4 2026, with 12-month data and the second co-primary endpoint due Q1 2027. The stakes are existential in both directions: Fractyl previously disclosed a going-concern warning and terminated its ATM, and received a Nasdaq delisting notice in September before executing a 1-for-12 reverse split on October 2. Positive pivotal data is the one asset that can justify raising the capital needed to reach a potential 2028 launch. The risk is that the company still has no approved product, no revenue, and must fund a De Novo review and commercial build-out on a micro-cap balance sheet.